Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropivacaine Nerve Block for Emergence Agitation in Septorhinoplasty
NCT02751268Phase 4Unknown
- Sponsor
- Armed Forces Hampyeong Hospital
- Start
- Apr 2016
- Primary completion
- Mar 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ropivacaine in Emergence agitation (EA) and postoperative pain (2 arms), sponsored by Armed Forces Hampyeong Hospital. Primary endpoint: Emergence Agitation Incidence at 2 hours. Status: unknown.
02
Drugs
ropivacaine
03
Conditions
Emergence agitation (EA)postoperative pain
Beyond the preview
Go deeper on NCT02751268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02751268.